Medpace Holdings, Inc. (MEDP) - Q2 2026 10-Q Summary
Business Context and Reporting Period
This filing covers the quarterly period ended June 30, 2026. Medpace Holdings, Inc. is a global clinical contract research organization (CRO) providing full-service Phase I-IV clinical development services to pharmaceutical, biotechnology, and medical device companies. The company operates across North America, Europe, and Asia with approximately 6,500 employees in 46 countries.
Key Financial Metrics
| Metric | Q2 2026 (3 Months) | Q2 2025 (3 Months) | YTD 2026 (6 Months) | YTD 2025 (6 Months) |
|---|---|---|---|---|
| Revenue, Net | $707.3 million | $603.3 million | $1,413.9 million | $1,161.9 million |
| Net Income | $121.4 million | $90.3 million | $245.2 million | $204.9 million |
| Diluted EPS | $4.25 | $3.10 | $8.53 | $6.79 |
| Operating Income | $146.8 million | $126.3 million | $288.3 million | $239.9 million |
| Operating Margin | 20.8% | 20.9% | 20.4% | 20.6% |
| Cash from Operations (YTD) | $313.8 million (vs. $274.4 million YTD 2025) | |||
| Cash & Equivalents (End of Period) | $502.7 million | |||
| Debt | No indebtedness under $10.0 million credit facility |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 17.2% in Q2 and 21.7% YTD compared to the prior year, driven by growth in Metabolic, Oncology, Central Nervous System, and AVAI therapeutic areas.
- Cost Structure: Total direct costs rose 19.5% in Q2 and 26.4% YTD, primarily due to higher reimbursed out-of-pocket expenses and increased personnel costs to support service growth.
- SG&A Efficiency: Selling, general, and administrative expenses decreased 8.2% YTD, largely due to a $12.9 million reduction in stock-based compensation expense.
- Backlog: Backlog increased 4.9% to $3.01 billion as of June 30, 2026, with approximately $1.95 billion to $1.97 billion expected to convert to revenue in the next 12 months.
- Share Repurchases: The company repurchased 705,616 shares for $294.7 million in Q2 2026. YTD repurchases totaled $294.8 million, a significant reduction from $912.8 million in the same period in 2025.
Outlook, Risks, and Contingencies
- Guidance: The filing does not provide specific numerical guidance for future periods but states expectations to fund operations through cash flow and existing credit facilities.
- Legal Proceedings: Two lawsuits were filed in 2026 alleging violations of the Securities Exchange Act regarding the company's book-to-bill ratio disclosures. The company believes potential losses are not currently probable or reasonably estimable and has not recognized a liability.
- Tax Environment: The company noted the enactment of the "One Big Beautiful Bill Act" (OBBBA) in July 2025, which includes permanent extensions of certain tax provisions. The effective tax rate for Q2 2026 was 20.0%.
- Liquidity: The company maintains a strong liquidity position with $502.7 million in cash and a $10.0 million unsecured credit facility with no outstanding borrowings.
Investor Verification Checklist
- Verify the sustainability of revenue growth in Metabolic and Oncology segments given the high reliance on reimbursed out-of-pocket expenses.
- Monitor the status of the two pending securities class action lawsuits regarding book-to-bill ratio disclosures.
- Assess the impact of the reduced share repurchase pace ($294.8M YTD 2026 vs. $912.8M YTD 2025) on capital allocation strategy.
- Review the conversion rate of the $3.01 billion backlog into actual revenue over the next 12 months.
- Confirm the continued effectiveness of cost controls in SG&A, specifically regarding stock-based compensation volatility.